AUC-Guided Vancomycin Dosing Improves Targets in Critically Ill
This before-after study evaluates whether Bayesian model-informed precision dosing of vancomycin reduces acute kidney injury and improves target attainment in a predominantly non-MRSA intensive care population.
Vancomycin is crucial for treating gram-positive infections but can cause acute kidney injury (AKI); optimizing dosing may improve safety. Model-informed AUC-based dosing reduced AKI incidence from 27.8% to 14%, and increased target attainment to 70.2% from 55.1%. The study suggests that AUC24-guided dosing can enhance vancomycin safety and efficacy, warranting broader implementation despite limited MRSA prevalence. AUC24-based vancomycin dosing improves safety and target attainment in critically ill patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Gundlach L, Kunkel M, Scherf-Clavel O, Surat G
Citation:Gundlach L, Kunkel M, Scherf-Clavel O, et al. Model-informed AUC-guided dosing for parenteral vancomycin in critically ill patients: impact on target attainment and renal safety - a pre-post intervention study. BMC pharmacology & toxicology. 2026;27(1). doi:10.1186/s40360-026-01224-x
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.